The MarketWatch News Department was not involved in the creation of this content.-- Wegovy(R) (semaglutide injection) granted conditional marketing authorization for the treatment ...

Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

Altimmune said on Friday its experimental liver disease drug improved signs of scarring and ‍health of the organ after 48 weeks of treatment in a mid-stage study, sending the company's shares up more ...

Altimmune said on Friday its experimental liver disease drug led to weight loss and improved markers for scarring and health of the organ based on non-invasive tests after 48 weeks of treatment in a ...

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...

At present, around 59 million adults worldwide have diabetes, about 64 million are diagnosed with heart failure, and ...

We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...

Novo Nordisk’s Wegovy® (semaglutide 2.4 mg) was associated with liver health–related benefits not solely driven by weight loss in adult patients with metabolic dysfunction-associated steatohepatitis ...

Geneticist Michael Klotsman was frustrated by human drug development. That led him to launch a startup focused on treatments ...

The past 18 months have been absolutely terrible for Novo Nordisk (NYSE: NVO). The Denmark-based drugmaker has faced poor ...

Novo Nordisk (NYSE:NVO) is one of the most profitable large cap stocks to buy right now. On November 10, Novo Nordisk announced new post hoc analysis data from the ESSENCE Phase 3 trial regarding the ...

This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients. Semaglutide is Novo Nordisk's largest growth driver, and it has not performed ...